The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) β-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.

中文翻译：

---

病毒感染后给予干扰素-β-1a对严重急性呼吸系统综合症冠状病毒2的体外抑制作用。

正在进行的2019年冠状病毒疾病大流行已迫使临床和科学界尝试将现有抗病毒药物重新用于治疗严重急性呼吸综合征-冠状病毒2（SARS-CoV-2）的快速选择。在这种情况下，其抗病毒潜能已知的干扰素（IFN）β-1a可能是潜在的候选药物，它是目前在多发性硬化症临床管理中使用的药物。在本报告中，我们证明了在感染病毒后，以临床上可达到的浓度，IFN-β-1a在抑制体外SARS-CoV-2复制方面非常有效。